Modelling ageing and age-related disease

Q3 Pharmacology, Toxicology and Pharmaceutics

Drug Discovery Today: Disease Models Pub Date : 2016-06-01 DOI:10.1016/j.ddmod.2017.07.005

Ilaria Bellantuono , Paul K. Potter

引用次数: 6

Abstract

An increased lifespan comes with an associated increase in disease incidence, and is the major risk factor for age-related diseases. To face this societal challenge search for new treatments has intensified requiring good preclinical models, whose complexity and accuracy is increasing. However, the influence of ageing is often overlooked. Furthermore, phenotypic assessment of ageing models is in need of standardisation to enable the accurate evaluation of pre-clinical intervention studies in line with clinical translation.

查看原文本刊更多论文

模拟衰老和与年龄有关的疾病

寿命的延长与疾病发病率的增加有关，是与年龄有关的疾病的主要危险因素。为了应对这一社会挑战，对新疗法的研究已经加强，需要良好的临床前模型，其复杂性和准确性正在增加。然而，老龄化的影响往往被忽视。此外，衰老模型的表型评估需要标准化，以使临床前干预研究的准确评估符合临床转化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today: Disease Models Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

自引率

0.00%

发文量

期刊介绍： Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.